Bone Biologics Corp (BBLG): Nasdaq/NYSE listing notice — Bone Biologics receives Nasdaq delisting notice for bid price below $1; plans reverse stock split

Bone Biologics Corp

Received Nasdaq deficiency letter on April 7, 2025 for failing minimum bid price of $1 per share for 30 consecutive business days.
Has 180-day compliance period until October 6, 2025 to regain compliance by closing bid price >= $1 for 10 consecutive business days.
Intends to seek stockholder approval for a reverse stock split at upcoming annual meeting to increase share price.
No immediate effect on listing; if not compliant, Nasdaq may delist, subject to appeal.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bone Biologics Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 7, 2025, Bone Biologics Corporation (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 6, 2025, in which to regain compliance with the minimum bid price req

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bone Biologics Corp filing history →

Source: SEC EDGAR

accession 0001641172-25-003880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.